1. A structural component comprising a tubular section composed of at least two materials having different stiffnesses andor creeping strengths, wherein the materials contain thermoplastic synthetic materials and one of the materials having a greater stiffness andor creeping strength is embedded in the other material, the tubular section comprising an annular surface extending continuously and coaxially to the longitudinal center axis of the structural component, wherein the annular surface is of a material which is the same as the material injection molded over the annular surface in a predetermined quantity ratio relative to the outer material, or wherein between 40% and 100% of the annular surface are composed of the injected material and are distributed in uniform spacings in a circumferential direction of the annular surface.
2. The structural component according to claim 1, wherein the annular surface is covered by a synthetic material subsequently injected into the inner synthetic material over the annular surface, wherein the synthetic material is the same as the outer synthetic material.
3. The structural component according to claim 1, wherein a quantity ratio of the embedded material relative to the outer material is in the range of 10% to 90%.
4. The structural component according to claim 1, wherein the embedded material is selected from the group consisting of polyamide (PA), reinforced polyamide, polyethylene (PE), reinforced polyethylene, polypropylene (PP), reinforced polypropylene, polyethylene terephthalate (PET), ethylene vinyl alcohol (EVOH), polybutylene naphthalate (PBN), polyethylene naphthalate (PEN), polyoximethylene (POM), polyphenylene sulfide (PPS), and fluorothermoplastic material.
5. The structural component according to claim 1, wherein the outer material is selected from the group consisting of polyolefin, thermoplastic elastomer, non-reinforced polyamide, thermoplastic polyester, and thermoplastic polyester elastomer.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A crystalline form of Vemurafenib hydrochloride salt, designated as Form II, characterized by one or more of the following:
a powder X-ray diffraction pattern having peaks at 5.0, 9.9, 15.7, 19.8 and 22.1 degrees two theta\xb10.2 degrees two theta;
a powder X-ray diffraction pattern substantially as depicted in FIG. 1;
a solid-state 13C NMR spectrum having characteristic peaks at 51.0, 114.5, 132.3, 138.0 and 139.5 ppm, \xb10.2 ppm;
a solid state 13C NMR spectrum having chemical shift differences between said characteristic peaks and a peak at 120.9 ppm\xb10.2 ppm of \u221269.9, \u22126.4, 11.4, 17.1 and 18.6\xb10.1 ppm, respectively;
a solid state 13C NMR spectrum substantially as shown in FIG. 3;
or any combination of these data.
2. The crystalline form of claim 1, characterized by a powder X-ray diffraction pattern having peaks at 5.0, 9.9, 15.7, 19.8 and 22.1, further characterized by an additional one, two, three, four or five PXRD peaks selected from 18.5, 20.4, 21.0, 23.8 and 26.7 degrees two theta\xb10.2 degrees two theta.
3. The crystalline form of claim 1, further characterized by one or more of the following:
a DSC thermogram substantially as depicted in FIG. 2;
a broad dehydrochlorination DSC endotherm between 166\xb0 C. (\xb15\xb0 C.) and 197\xb0 C. (\xb15\xb0 C.),
a DSC melting peak at about 270.8\xb0 C. (\xb11\xb0 C.), and DSC melting onset at about 268.1\xb0 C. (\xb11\xb0 C.),
or a combination thereof.
4. The crystalline form of claim 1, wherein the crystalline form is an anhydrous form.
5. A pharmaceutical composition comprising the crystalline form of Vemurafenib hydrochloride according to claim 1.
6. A pharmaceutical formulation comprising
the crystalline form of Vemurafenib hydrochloride according to claim 1, or a pharmaceutical composition comprising the crystalline form of Vemurafenib hydrochloride according to claim 1,
and at least one pharmaceutically acceptable excipient.
7. (canceled)
8. A process for preparing the pharmaceutical formulation according to claim 6 comprising
combining the crystalline form of Vemurafenib hydrochloride or the pharmaceutical composition, with at least one pharmaceutically acceptable excipient.
9. (canceled)
10. (canceled)
11. A method of treating a subject suffering from cancer, comprising administering to the subject a therapeutically effective amount of
a crystalline form of Vemurafenib hydrochloride according to claim 1,
a pharmaceutical composition comprising a crystalline form of Vemurafenib hydrochloride according to claim 1
a pharmaceutical formulation comprising a crystalline form of Vemurafenib hydrochloride according to claim 1 and at least one pharmaceutically acceptable excipient
or a pharmaceutical formulation comprising a pharmaceutical composition comprising a crystalline form of Vemurafenib hydrochloride according to claim 1 and at least one pharmaceutically acceptable excipient.
12. (canceled)
13. A process for preparing Vemurafenib comprising
preparing a crystalline form of Vemurafenib hydrochloride according to claim 1, and
converting the crystalline form of Vemurafenib hydrochloride to Vemurafenib.
14. The process according to claim 13, wherein the conversion is accomplished by a process comprising basifying the crystalline form of Vemurafenib hydrochloride to obtain the Vemurafenib.
15. A process for preparing a Vemurafenib salt comprising
preparing a crystalline form of Vemurafenib hydrochloride according to claim 1, and
converting the crystalline form of Vemurafenib hydrochloride to the Vemurafenib salt.
16. The process according to claim 15, wherein the conversion is accomplished by a process comprising basifying the crystalline form of Vemurafenib hydrochloride to obtain Vemurafenib and adding an acid or a base to obtain the Vemurafenib as the addition or base addition salt.